3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Breast
2
Tumor-Agnostic
1
Conditions
Breast Neoplasms
28
Neoplasms by Site
2
Neoplasms
2
Neoplasm Metastasis
2
Breast Diseases
2
Advanced Breast Cancer
2
Sleep Wake Disorders
1
Skin Diseases
1
Sexual Dysfunctions, Psychological
1
Inflammatory Breast Neoplasms
1
Hormone-receptor-positive Breast Cancer
1
Highly Endocrine Responsive Operable Breast Cancer
1
Fatigue
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Carcinoma, Ductal, Breast
1
Breast Neoplasms, Male
1
Anatomic Stage III Breast Cancer AJCC v8
1
Interventions
Paclitaxel
26
pembrolizumab
24
Docetaxel
20
Capecitabine
19
Fulvestrant
17
Trastuzumab
16
Anastrozole
15
Cyclophosphamide
14
Lapatinib
13
Letrozole
11
Carboplatin
11
Radiotherapy
10
Doxorubicin
10
palbociclib
9
Therapeutics
9
Nivolumab
9
Exercise
9
Gemcitabine
8
Cisplatin
8
Blood Specimen Collection
8
Tamoxifen
7
Bevacizumab
7
liposomal doxorubicin
6
exemestane
6
abemaciclib
6
Vinorelbine
6
Standard of Care
6
Fluorouracil
6
atezolizumab
5
Surveys and Questionnaires
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Gonadotropin-Releasing Hormone
×
Breast
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled